Jeff Alexander

Title: Innovations of Jeff Alexander in Adenoviral-Based Vectors

Introduction

Jeff Alexander is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of adenoviral-based vectors. His work focuses on creating innovative solutions for vaccination against infectious pathogens.

Latest Patents

Jeff Alexander holds a patent for adenoviral-based vectors. This invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as the influenza virus. The adenoviral vectors can be utilized to vaccinate subjects against these infectious pathogens. They comprise heterologous sequences encoding the antigens, which can be inserted into various locations within the adenoviral vectors. This includes specific E3 deletions and integration into the adenoviral hexon coding region. The vectors can be derived from any adenoviral serotype, with a particular focus on Ad4 or Ad7 serotypes.

Career Highlights

Jeff Alexander is associated with Paxvax, Inc., where he continues to advance his research and development efforts. His work has the potential to impact public health by providing effective vaccination strategies against infectious diseases.

Collaborations

Jeff collaborates with Timothy P Mayall, contributing to the innovative research environment at Paxvax, Inc. Their combined expertise enhances the development of groundbreaking solutions in the field of biotechnology.

Conclusion

Jeff Alexander's contributions to adenoviral-based vectors exemplify the innovative spirit of modern biotechnology. His work not only advances scientific knowledge but also holds promise for improving public health through effective vaccination strategies.